Te Boekhorst Paul Francis Olivier reported option exercise involving 16,393 derivative units of IMMUCELL CORP DE at $0.00 for $0 on Nov 12, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
President and CEO
President and CEO
Filed Nov 16, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
16,393Incentive Stock Options (Right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
57,884Direct
Trade date
Nov 12, 2026Option exercise
Filed
Nov 16, 2026, 1:54 PM ET4-day reporting delay
Accession
0001437749-26-037085Code M · Transaction 401774
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 12, 2026Option exercise16,393$6.10$99,997.30Trade 401773
2 transaction rows in this filing. Joint filers share the same rows.

ICCC price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ICCC · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 23, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: Total beneficial ownership shown here reflects a correction in the amount previously reported June 22, 2026 on Form 4 (which correctly reported the number of shares purchases but overstated total ownership by 47 shares). F2: The stock option vests in three annual installments of 24.759 shares on the first, second and third anniversaries of the November 7, 2026 grant date. The first installment vested on November7, 2026. F3: Represents the number of shares remaining subject to the option following the reported exercise.